Effects of neoadjuvant chemotherapy on the prognostic mortality risk of invasive transitional bladder cancer: a meta-analysis
To systematically assess the effects of neoadjuvant chemotherapy on the prognostic risk of invasive transitional bladder cancer. All known randomized controlled trials (RCTs) on neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer, published from the date of database bui...
Gespeichert in:
| Veröffentlicht in: | Zhong hua yi xue za zhi 2013-06, Vol.93 (22), p.1705-1710 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1710 |
|---|---|
| container_issue | 22 |
| container_start_page | 1705 |
| container_title | Zhong hua yi xue za zhi |
| container_volume | 93 |
| creator | Fan, Bo Zhang, Liang Li, Xian-cheng Song, Yong-sheng Guo, En-zhong Pan, Tao Shen, Liang Xin, Shi-yong Song, Xi-shuang Wang, Jian-bo |
| description | To systematically assess the effects of neoadjuvant chemotherapy on the prognostic risk of invasive transitional bladder cancer.
All known randomized controlled trials (RCTs) on neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer, published from the date of database building to September 2012, were retrieved from such databanks as Pubmed, CBMdisc, Embase and Cochrane. The data on 5-year survival rate of included studies were extracted for further heterogeneity exploration, subgroup analysis and statistical pooling with the RevMan 5.10 software.
Fourteen subjects involving 2072 cases and 2086 controls were published from 1991 to 2012. The overall odds ratio of survival suggested a 21% relative reduction in mortality risk for neoadjuvant chemotherapy compared to that on control (OR = 0.79, 95%CI:0.70-0.90). In subgroup analysis according to different neoadjuvant chemotherapies, MCV (methotrexate, cisplatin and vinblastine) and MVAC (methotrexate, vinblastine, adriamycin and cisplat |
| doi_str_mv | 10.3760/cma.j.issn.0376-2491.2013.22.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1444000078</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1444000078</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-9a2541c6fb31cfbdec11508f1b5b83edaf1047aadf86614bb256afc7aed6573d3</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRb0A0ar0F5CX3STYjuOk7FBVHlIlNrCOxi_qkjjBditlwb8TRGE2M7pz50pnEFpRkheVILeqg_yQuxh9TiYhY3xNc0ZokTOWE1JdoPm_PkPLGJ0kvCrWjDB6hWaMU8ZFJeboa2utUSni3mJvetCH4wl8wmpvuj7tTYBhxL3H04iH0L_7PiancNeHBK1LIw4ufvwcO3-C6E4GpwA-uuR6Dy2WLWhtAlbglQl3GHBnEmQw7cbo4jW6tNBGszz3BXp72L5unrLdy-Pz5n6XDZSJlK2BlZwqYWVBlZXaKEpLUlsqS1kXRoOlEx2AtrUQlEvJSgFWVWC0KKtCFwu0-s2dED6PJqamc1GZtoWJ-RgbyjknU1X1ZL05W4-yM7oZgusgjM3fy4pvrtV1GQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1444000078</pqid></control><display><type>article</type><title>Effects of neoadjuvant chemotherapy on the prognostic mortality risk of invasive transitional bladder cancer: a meta-analysis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Fan, Bo ; Zhang, Liang ; Li, Xian-cheng ; Song, Yong-sheng ; Guo, En-zhong ; Pan, Tao ; Shen, Liang ; Xin, Shi-yong ; Song, Xi-shuang ; Wang, Jian-bo</creator><creatorcontrib>Fan, Bo ; Zhang, Liang ; Li, Xian-cheng ; Song, Yong-sheng ; Guo, En-zhong ; Pan, Tao ; Shen, Liang ; Xin, Shi-yong ; Song, Xi-shuang ; Wang, Jian-bo</creatorcontrib><description>To systematically assess the effects of neoadjuvant chemotherapy on the prognostic risk of invasive transitional bladder cancer.
All known randomized controlled trials (RCTs) on neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer, published from the date of database building to September 2012, were retrieved from such databanks as Pubmed, CBMdisc, Embase and Cochrane. The data on 5-year survival rate of included studies were extracted for further heterogeneity exploration, subgroup analysis and statistical pooling with the RevMan 5.10 software.
Fourteen subjects involving 2072 cases and 2086 controls were published from 1991 to 2012. The overall odds ratio of survival suggested a 21% relative reduction in mortality risk for neoadjuvant chemotherapy compared to that on control (OR = 0.79, 95%CI:0.70-0.90). In subgroup analysis according to different neoadjuvant chemotherapies, MCV (methotrexate, cisplatin and vinblastine) and MVAC (methotrexate, vinblastine, adriamycin and cisplat</description><identifier>ISSN: 0376-2491</identifier><identifier>DOI: 10.3760/cma.j.issn.0376-2491.2013.22.007</identifier><identifier>PMID: 24124676</identifier><language>chi</language><publisher>China</publisher><subject>Humans ; Neoadjuvant Therapy - mortality ; Prognosis ; Randomized Controlled Trials as Topic ; Survival Rate ; Treatment Outcome ; Urinary Bladder Neoplasms - mortality ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - therapy</subject><ispartof>Zhong hua yi xue za zhi, 2013-06, Vol.93 (22), p.1705-1710</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24124676$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fan, Bo</creatorcontrib><creatorcontrib>Zhang, Liang</creatorcontrib><creatorcontrib>Li, Xian-cheng</creatorcontrib><creatorcontrib>Song, Yong-sheng</creatorcontrib><creatorcontrib>Guo, En-zhong</creatorcontrib><creatorcontrib>Pan, Tao</creatorcontrib><creatorcontrib>Shen, Liang</creatorcontrib><creatorcontrib>Xin, Shi-yong</creatorcontrib><creatorcontrib>Song, Xi-shuang</creatorcontrib><creatorcontrib>Wang, Jian-bo</creatorcontrib><title>Effects of neoadjuvant chemotherapy on the prognostic mortality risk of invasive transitional bladder cancer: a meta-analysis</title><title>Zhong hua yi xue za zhi</title><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><description>To systematically assess the effects of neoadjuvant chemotherapy on the prognostic risk of invasive transitional bladder cancer.
All known randomized controlled trials (RCTs) on neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer, published from the date of database building to September 2012, were retrieved from such databanks as Pubmed, CBMdisc, Embase and Cochrane. The data on 5-year survival rate of included studies were extracted for further heterogeneity exploration, subgroup analysis and statistical pooling with the RevMan 5.10 software.
Fourteen subjects involving 2072 cases and 2086 controls were published from 1991 to 2012. The overall odds ratio of survival suggested a 21% relative reduction in mortality risk for neoadjuvant chemotherapy compared to that on control (OR = 0.79, 95%CI:0.70-0.90). In subgroup analysis according to different neoadjuvant chemotherapies, MCV (methotrexate, cisplatin and vinblastine) and MVAC (methotrexate, vinblastine, adriamycin and cisplat</description><subject>Humans</subject><subject>Neoadjuvant Therapy - mortality</subject><subject>Prognosis</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Urinary Bladder Neoplasms - mortality</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - therapy</subject><issn>0376-2491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAQRb0A0ar0F5CX3STYjuOk7FBVHlIlNrCOxi_qkjjBditlwb8TRGE2M7pz50pnEFpRkheVILeqg_yQuxh9TiYhY3xNc0ZokTOWE1JdoPm_PkPLGJ0kvCrWjDB6hWaMU8ZFJeboa2utUSni3mJvetCH4wl8wmpvuj7tTYBhxL3H04iH0L_7PiancNeHBK1LIw4ufvwcO3-C6E4GpwA-uuR6Dy2WLWhtAlbglQl3GHBnEmQw7cbo4jW6tNBGszz3BXp72L5unrLdy-Pz5n6XDZSJlK2BlZwqYWVBlZXaKEpLUlsqS1kXRoOlEx2AtrUQlEvJSgFWVWC0KKtCFwu0-s2dED6PJqamc1GZtoWJ-RgbyjknU1X1ZL05W4-yM7oZgusgjM3fy4pvrtV1GQ</recordid><startdate>20130611</startdate><enddate>20130611</enddate><creator>Fan, Bo</creator><creator>Zhang, Liang</creator><creator>Li, Xian-cheng</creator><creator>Song, Yong-sheng</creator><creator>Guo, En-zhong</creator><creator>Pan, Tao</creator><creator>Shen, Liang</creator><creator>Xin, Shi-yong</creator><creator>Song, Xi-shuang</creator><creator>Wang, Jian-bo</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20130611</creationdate><title>Effects of neoadjuvant chemotherapy on the prognostic mortality risk of invasive transitional bladder cancer: a meta-analysis</title><author>Fan, Bo ; Zhang, Liang ; Li, Xian-cheng ; Song, Yong-sheng ; Guo, En-zhong ; Pan, Tao ; Shen, Liang ; Xin, Shi-yong ; Song, Xi-shuang ; Wang, Jian-bo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-9a2541c6fb31cfbdec11508f1b5b83edaf1047aadf86614bb256afc7aed6573d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2013</creationdate><topic>Humans</topic><topic>Neoadjuvant Therapy - mortality</topic><topic>Prognosis</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Urinary Bladder Neoplasms - mortality</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>Fan, Bo</creatorcontrib><creatorcontrib>Zhang, Liang</creatorcontrib><creatorcontrib>Li, Xian-cheng</creatorcontrib><creatorcontrib>Song, Yong-sheng</creatorcontrib><creatorcontrib>Guo, En-zhong</creatorcontrib><creatorcontrib>Pan, Tao</creatorcontrib><creatorcontrib>Shen, Liang</creatorcontrib><creatorcontrib>Xin, Shi-yong</creatorcontrib><creatorcontrib>Song, Xi-shuang</creatorcontrib><creatorcontrib>Wang, Jian-bo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhong hua yi xue za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fan, Bo</au><au>Zhang, Liang</au><au>Li, Xian-cheng</au><au>Song, Yong-sheng</au><au>Guo, En-zhong</au><au>Pan, Tao</au><au>Shen, Liang</au><au>Xin, Shi-yong</au><au>Song, Xi-shuang</au><au>Wang, Jian-bo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of neoadjuvant chemotherapy on the prognostic mortality risk of invasive transitional bladder cancer: a meta-analysis</atitle><jtitle>Zhong hua yi xue za zhi</jtitle><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><date>2013-06-11</date><risdate>2013</risdate><volume>93</volume><issue>22</issue><spage>1705</spage><epage>1710</epage><pages>1705-1710</pages><issn>0376-2491</issn><abstract>To systematically assess the effects of neoadjuvant chemotherapy on the prognostic risk of invasive transitional bladder cancer.
All known randomized controlled trials (RCTs) on neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer, published from the date of database building to September 2012, were retrieved from such databanks as Pubmed, CBMdisc, Embase and Cochrane. The data on 5-year survival rate of included studies were extracted for further heterogeneity exploration, subgroup analysis and statistical pooling with the RevMan 5.10 software.
Fourteen subjects involving 2072 cases and 2086 controls were published from 1991 to 2012. The overall odds ratio of survival suggested a 21% relative reduction in mortality risk for neoadjuvant chemotherapy compared to that on control (OR = 0.79, 95%CI:0.70-0.90). In subgroup analysis according to different neoadjuvant chemotherapies, MCV (methotrexate, cisplatin and vinblastine) and MVAC (methotrexate, vinblastine, adriamycin and cisplat</abstract><cop>China</cop><pmid>24124676</pmid><doi>10.3760/cma.j.issn.0376-2491.2013.22.007</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-2491 |
| ispartof | Zhong hua yi xue za zhi, 2013-06, Vol.93 (22), p.1705-1710 |
| issn | 0376-2491 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_1444000078 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Humans Neoadjuvant Therapy - mortality Prognosis Randomized Controlled Trials as Topic Survival Rate Treatment Outcome Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - therapy |
| title | Effects of neoadjuvant chemotherapy on the prognostic mortality risk of invasive transitional bladder cancer: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T00%3A08%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20neoadjuvant%20chemotherapy%20on%20the%20prognostic%20mortality%20risk%20of%20invasive%20transitional%20bladder%20cancer:%20a%20meta-analysis&rft.jtitle=Zhong%20hua%20yi%20xue%20za%20zhi&rft.au=Fan,%20Bo&rft.date=2013-06-11&rft.volume=93&rft.issue=22&rft.spage=1705&rft.epage=1710&rft.pages=1705-1710&rft.issn=0376-2491&rft_id=info:doi/10.3760/cma.j.issn.0376-2491.2013.22.007&rft_dat=%3Cproquest_pubme%3E1444000078%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1444000078&rft_id=info:pmid/24124676&rfr_iscdi=true |